Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,504 active trials253 approved drugs3,568 evidence items
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,622 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00043381 | Decitabine Versus Supportive Care in Adults With Advanced-stage MDS | completed | Phase 3 | 160 | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT03723941 | Adjuvant Chemotherapy vs. Observation/Mitotane After Primary Surgical Resection of Localized Adrenocortical CarcInoma(ACACIA) | completed | Phase 3 | 40 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 |
| Aug 1, 2024 |
| clinicaltrials |
| NCT04799249 | Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)(PRESERVE 2) | completed | Phase 3 | 194 | G1 Therapeutics, Inc.INDUSTRY | 11 | Aug 1, 2024 | clinicaltrials |
| NCT02323022 | Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML) | completed | Phase 3 | 618 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT02773849 | ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) | completed | Phase 3 | 157 | Ferring PharmaceuticalsINDUSTRY | 1 | Jul 29, 2024 | clinicaltrials |
| NCT02135419 | Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions(ANCHOR) | completed | Phase 3 | 4,446 | AIDS Malignancy ConsortiumNETWORK | 2 | Jul 26, 2024 | clinicaltrials |
| NCT03830866 | Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)(CALLA) | completed | Phase 3 | 770 | AstraZenecaINDUSTRY | 15 | Jul 26, 2024 | clinicaltrials |
| NCT04957212 | Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer | completed | Phase 3 | 214 | CinnagenINDUSTRY | 1 | Jul 26, 2024 | clinicaltrials |
| NCT01839773 | Phase 3 Study to Compare Efficacy and Safety of DHP107 vs. Taxol® in Patients With Metastatic or Recurrent Gastric Cancer(DREAM) | completed | Phase 3 | 238 | Daehwa Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 25, 2024 | clinicaltrials |
| NCT03306394 | A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic).(PRECONNECT) | completed | Phase 3 | 907 | Institut de Recherches Internationales ServierOTHER | 16 | Jul 25, 2024 | clinicaltrials |
| NCT02501954 | Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol | completed | Phase 3 | 48 | Women's Cancer Care Associates, LLCOTHER | 2 | Jul 23, 2024 | clinicaltrials |
| NCT02856126 | HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC | completed | Phase 3 | 214 | Sun Yat-sen UniversityOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT00551928 | Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients(MPRvsMEL200) | completed | Phase 3 | 402 | Fondazione EMN Italy OnlusOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT02215980 | STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS | completed | Phase 3 | 210 | Fondazione EMN Italy OnlusOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT04194203 | A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151) | completed | Phase 3 | 305 | Hoffmann-La RocheINDUSTRY | 1 | Jul 19, 2024 | clinicaltrials |
| NCT03195491 | A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia(CheckMate870) | completed | Phase 3 | 400 | Bristol-Myers SquibbINDUSTRY | 2 | Jul 18, 2024 | clinicaltrials |
| NCT05283837 | A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,) | completed | Phase 3 | 268 | Zydus Lifesciences LimitedINDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT01231347 | QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas(GAMMA) | completed | Phase 3 | 800 | NantCell, Inc.INDUSTRY | 32 | Jul 16, 2024 | clinicaltrials |
| NCT04028050 | A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer(MAURIS) | completed | Phase 3 | 155 | Hoffmann-La RocheINDUSTRY | 1 | Jul 16, 2024 | clinicaltrials |
| NCT00557193 | Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | completed | Phase 3 | 218 | Children's Oncology GroupNETWORK | 4 | Jul 15, 2024 | clinicaltrials |
| NCT03389451 | 68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer | completed | Phase 2 / Phase 3 | 30 | Michael Graham PhD, MDOTHER | 1 | Jul 12, 2024 | clinicaltrials |
| NCT04055142 | Clinical Trial for Evaluating the Efficacy and Safety of Electrocoagulation vs Topic Sinecatechins vs Topic Cidofovir Within the Treatment to High-grade Anal Intraepithelial Neoplasia in HIV Homosexual Males(TreatAIN) | completed | Phase 3 | 108 | Hospital Universitari Vall d'Hebron Research InstituteOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT04902885 | Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients | completed | Phase 3 | 95 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 10, 2024 | clinicaltrials |
| NCT03952091 | TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | completed | Phase 3 | 289 | TJ Biopharma Co., Ltd.INDUSTRY | 2 | Jul 3, 2024 | clinicaltrials |
| NCT00673335 | Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation(LIBER) | completed | Phase 3 | 170 | UNICANCEROTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT04233476 | 99mTc-3PRGD2 SPECT/CT for Integrin Imaging of Lung Cancer(TRIIL) | completed | Phase 3 | 409 | RDO Pharm.INDUSTRY | 1 | Jul 1, 2024 | clinicaltrials |
| NCT03425656 | Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer | completed | Phase 3 | 108 | AryoGen Pharmed Co.INDUSTRY | 1 | Jun 28, 2024 | clinicaltrials |
| NCT03579602 | Study of Tozuleristide and the Canvas Imaging System in Pediatric Subjects With CNS Tumors Undergoing Surgery | completed | Phase 2 / Phase 3 | 118 | Blaze Bioscience Inc.INDUSTRY | 1 | Jun 27, 2024 | clinicaltrials |
| NCT03493854 | A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer(FeDeriCa) | completed | Phase 3 | 500 | Hoffmann-La RocheINDUSTRY | 19 | Jun 26, 2024 | clinicaltrials |
| NCT03743051 | A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 318 | Helsinn Healthcare SAINDUSTRY | 7 | Jun 26, 2024 | clinicaltrials |
| NCT03743064 | A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 318 | Helsinn Healthcare SAINDUSTRY | 8 | Jun 26, 2024 | clinicaltrials |
| NCT03751124 | Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids | completed | Phase 3 | 229 | Myovant Sciences GmbHINDUSTRY | 8 | Jun 25, 2024 | clinicaltrials |
| NCT04642469 | Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.(MERMAID-2) | completed | Phase 3 | 30 | AstraZenecaINDUSTRY | 25 | Jun 25, 2024 | clinicaltrials |
| NCT02923258 | Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer | completed | Phase 2 / Phase 3 | 224 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT04047173 | RFA Versus SBRT for Recurrent Small HCC | completed | Phase 3 | 166 | Sun Yat-sen UniversityOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT02049905 | Phase 3 Study to Treat Patients With Soft Tissue Sarcomas | completed | Phase 3 | 433 | ImmunityBio, Inc.INDUSTRY | 13 | Jun 13, 2024 | clinicaltrials |
| NCT03950674 | Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study | completed | Phase 3 | 40 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Jun 10, 2024 | clinicaltrials |
| NCT02109146 | Postoperative TACE(Transhepatic Arterial Chemotherapy And Embolization) for Patients With Hepatocellular Carcinoma | completed | Phase 3 | 332 | Zhejiang UniversityOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT03234972 | A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 3 | 213 | Janssen Research & Development, LLCINDUSTRY | 2 | May 29, 2024 | clinicaltrials |
| NCT03084237 | Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer | completed | Phase 3 | 652 | Shanghai Henlius BiotechINDUSTRY | 3 | May 17, 2024 | clinicaltrials |
| NCT03849118 | 89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study(89ZR-TLX250) | completed | Phase 3 | 300 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 8 | May 17, 2024 | clinicaltrials |
| NCT01345175 | Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer | completed | Phase 3 | 69 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT01788020 | Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia | completed | Phase 3 | 202 | University of UlmOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT00112931 | Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma | completed | Phase 3 | 462 | University College, LondonOTHER | 3 | May 9, 2024 | clinicaltrials |
| NCT03412890 | LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids | completed | Phase 3 | 477 | Myovant Sciences GmbHINDUSTRY | 9 | May 9, 2024 | clinicaltrials |
| NCT00678327 | Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma | completed | Phase 3 | 1,202 | University College, LondonOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT04676334 | CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib(CATCH-R) | completed | Phase 3 | 34 | pharmaand GmbHINDUSTRY | 6 | May 7, 2024 | clinicaltrials |
| NCT03117049 | Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52) | completed | Phase 3 | 550 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 3 | May 6, 2024 | clinicaltrials |
| NCT00617981 | Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC) | completed | Phase 3 | 701 | ImunonINDUSTRY | 11 | May 3, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Aug 2, 2024source: clinicaltrials